The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome

The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjögren’s syndrome (SS) and the current availability of various biological agents (anti-TNF-α, IFN- α, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention....

Descripción completa

Detalles Bibliográficos
Autores principales: Meijer, Jiska M., Pijpe, Justin, Bootsma, Hendrika, Vissink, Arjan, Kallenberg, Cees G. M.
Formato: Texto
Lenguaje:English
Publicado: Humana Press Inc 2007
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2071970/
https://www.ncbi.nlm.nih.gov/pubmed/17992596
http://dx.doi.org/10.1007/s12016-007-8005-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2071970/
https://www.ncbi.nlm.nih.gov/pubmed/17992596
http://dx.doi.org/10.1007/s12016-007-8005-6

Ejemplares similares